- ISIN
- US45168D1046
- CUSIP
- 45168D104
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- IPO Date
- Jun 21, 1991
Highlights
- Market Cap
- $44.10B
- Enterprise Value
- $45.26B
- EPS (TTM)
- $20.36
- PE Ratio
- 27.45
- PEG Ratio
- 2.37
- Total Revenue (TTM)
- $4.45B
- Gross Profit (TTM)
- $2.76B
- EBITDA (TTM)
- $1.52B
- Year Range
- $518.55 - $769.98
- Target Price
- $747.50
- ROA (TTM)
- 32.35%
- ROE (TTM)
- 70.38%
- Avg. Volume (1M)
- 591K
- Avg. Volume Value (1M)
- $330.40M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
IDXX Performance Chart
IDEXX Laboratories, Inc. (IDXX) is down 17.4% since the beginning of the year. At $559 per share, IDXX is trading 27.4% below its 52-week high of $770. Investors who bought $1,000 worth of IDXX shares 5 years ago would now be looking at an investment worth $824.
Loading charts...
Compare this symbol against anything
Returns By Period
IDEXX Laboratories, Inc. (IDXX) has returned -17.36% so far this year and 4.39% over the past 12 months. Looking at the last ten years, IDXX has achieved an annualized return of 18.10%, outperforming the S&P 500 Index benchmark, which averaged 13.26% per year.
IDEXX Laboratories, Inc.
- 1D
- 0.05%
- 1M
- 0.23%
- 6M
- -16.61%
- YTD
- -17.36%
- 1Y
- 4.39%
- 3Y*
- 1.65%
- 5Y*
- -3.80%
- 10Y*
- 18.10%
- ALL TIME*
- 19.97%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
IDXX Monthly Returns History
Based on dividend-adjusted daily data since Jun 24, 1991, IDXX's average daily return is +0.11%, while the average monthly return is +2.13%. At this rate, an investment would double in approximately 2.7 years.
Historically, 59% of months were positive and 41% were negative. The best month was Feb 2000 with a return of +96.3%, while the worst month was Mar 1997 at -62.4%. The longest winning streak lasted 12 consecutive months, and the longest losing streak was 5 months.
On a daily basis, IDXX closed higher 51% of trading days. The best single day was Aug 4, 2025 with a return of +27.5%, while the worst single day was Mar 24, 1997 at -62.5%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -0.90% | -2.05% | -14.44% | -0.19% | 0.49% | -6.58% | 6.20% | -17.36% | |||||
| 2025 | 2.08% | 3.57% | -3.93% | 3.02% | 18.65% | 4.48% | -0.38% | 21.11% | -1.27% | -1.47% | 19.60% | -10.14% | 63.63% |
| 2024 | -7.20% | 11.68% | -6.14% | -8.74% | 0.85% | -1.96% | -2.27% | 1.09% | 4.96% | -19.46% | 3.64% | -1.97% | -25.51% |
| 2023 | 17.78% | -1.51% | 5.67% | -1.58% | -5.57% | 8.06% | 10.45% | -7.81% | -14.50% | -8.64% | 16.61% | 19.16% | 36.06% |
| 2022 | -22.96% | 4.94% | 2.76% | -21.31% | -9.03% | -10.44% | 13.81% | -12.92% | -6.28% | 10.40% | 18.40% | -4.21% | -38.04% |
| 2021 | -4.24% | 8.67% | -5.93% | 12.20% | 1.66% | 13.16% | 7.44% | -0.70% | -7.70% | 7.11% | -8.72% | 8.29% | 31.73% |
Benchmark Metrics
IDEXX Laboratories, Inc. has an annualized alpha of 19.52%, beta of 0.85, and R2 of 0.15 versus S&P 500 Index. Calculated based on daily prices since June 24, 1991.
- This stock captured 120.19% of S&P 500 Index gains but only 68.72% of its losses - a favorable profile for investors.
- R2 of 0.15 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 19.52%
- Beta
- 0.85
- R²
- 0.15
- Upside Capture
- 120.19%
- Downside Capture
- 68.72%
Return for Risk
Risk / Return Rank
IDXX ranks 48 for risk / return — above 48% of stocks peers on PortfoliosLab. Its historical combined result is near the middle of the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for IDEXX Laboratories, Inc. (IDXX) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| IDXX | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.31 | ||
| Sortino ratioReturn per unit of downside risk | -1.39 | ||
| Omega ratioGain probability vs. loss probability | 1.07 | 1.25 | -0.18 |
| Calmar ratioReturn relative to maximum drawdown | 0.15 | 2.00 | -1.85 |
| Martin ratioReturn relative to average drawdown | 0.25 | 8.49 | -8.24 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the IDEXX Laboratories, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the IDEXX Laboratories, Inc. was 81.42%, occurring on Apr 18, 1997. Recovery took 1735 trading sessions.
The current IDEXX Laboratories, Inc. drawdown is 27.08%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-81.42%Apr 1997 | 1y 2mo | 6y 11mo | 8y 1moFeb 1996 - Mar 2004 | — |
-57.28%Nov 2008 | 1y 5d | 1y 5mo | 2y 5moNov 2007 - Apr 2010 | Financial crisis2007–2009 |
-54.00%Oct 2022 | 1y 2mo | 3y 21d | 4y 3moAug 2021 - Nov 2025 | Bear market2022 |
-37.13%Mar 2020 | 1mo 2d | 1mo 15d | 2mo 17dFeb 2020 - May 2020 | COVID crash2020 |
-35.34%Apr 1992 | 5mo 18d | 6mo 23d | 1y 6dNov 1991 - Nov 1992 | — |
Drawdown Indicators
| IDXX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -81.42% | -56.78% | -24.64% |
Max Drawdown (1Y)Largest decline over 1 year | -31.34% | -9.10% | -22.24% |
Max Drawdown (3Y)Largest decline over 3 years | -37.41% | -18.90% | -18.51% |
Max Drawdown (5Y)Largest decline over 5 years | -54.00% | -25.43% | -28.57% |
Max Drawdown (10Y)Largest decline over 10 years | -54.00% | -33.92% | -20.08% |
Current DrawdownCurrent decline from peak | -27.08% | -1.58% | -25.50% |
Average DrawdownAverage peak-to-trough decline | -21.03% | -10.70% | -10.33% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 18.32% | 2.14% | +16.18% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of IDEXX Laboratories, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how IDEXX Laboratories, Inc. is priced in the market compared to other companies in the Diagnostics & Research industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for IDXX, comparing it with other companies in the Diagnostics & Research industry. Currently, IDXX has a P/E ratio of 27.5. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for IDXX compared to other companies in the Diagnostics & Research industry. IDXX currently has a PEG ratio of 2.4. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for IDXX relative to other companies in the Diagnostics & Research industry. Currently, IDXX has a P/S ratio of 6.8. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with IDXX
Add IDEXX Laboratories, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with IDXX